293 related articles for article (PubMed ID: 20188100)
1. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Richardson P; El-Serag HB
Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100
[TBL] [Abstract][Full Text] [Related]
2. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
[TBL] [Abstract][Full Text] [Related]
3. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
4. Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.
Loomans-Kropp HA; Chaloux M; Richmond E; Umar A
Cancer Prev Res (Phila); 2021 Feb; 14(2):195-204. PubMed ID: 32998939
[TBL] [Abstract][Full Text] [Related]
5. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
7. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Schwartz J; Richardson P; El-Serag HB
Dig Dis Sci; 2010 Dec; 55(12):3404-7. PubMed ID: 20397052
[TBL] [Abstract][Full Text] [Related]
8. Medication usage and the risk of neoplasia in patients with Barrett's esophagus.
Nguyen DM; El-Serag HB; Henderson L; Stein D; Bhattacharyya A; Sampliner RE
Clin Gastroenterol Hepatol; 2009 Dec; 7(12):1299-304. PubMed ID: 19523538
[TBL] [Abstract][Full Text] [Related]
9. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study.
Beales IL; Vardi I; Dearman L; Broughton T
Dis Esophagus; 2013; 26(8):838-46. PubMed ID: 22989236
[TBL] [Abstract][Full Text] [Related]
10. Statin use is associated with a decreased risk of Barrett's esophagus.
Nguyen T; Khalaf N; Ramsey D; El-Serag HB
Gastroenterology; 2014 Aug; 147(2):314-23. PubMed ID: 24798416
[TBL] [Abstract][Full Text] [Related]
11. Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
Beales IL; Dearman L; Vardi I; Loke Y
Dig Dis Sci; 2016 Jan; 61(1):238-46. PubMed ID: 26386857
[TBL] [Abstract][Full Text] [Related]
12. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Beales IL; Vardi I; Dearman L
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):917-23. PubMed ID: 22569083
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Wang F; Lv ZS; Fu YK
Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.
Liao LM; Vaughan TL; Corley DA; Cook MB; Casson AG; Kamangar F; Abnet CC; Risch HA; Giffen C; Freedman ND; Chow WH; Sadeghi S; Pandeya N; Whiteman DC; Murray LJ; Bernstein L; Gammon MD; Wu AH
Gastroenterology; 2012 Mar; 142(3):442-452.e5; quiz e22-3. PubMed ID: 22108196
[TBL] [Abstract][Full Text] [Related]
16. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
[TBL] [Abstract][Full Text] [Related]
17. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
[TBL] [Abstract][Full Text] [Related]
18. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
19. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
20. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]